20:23:02 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MDGL - MADRIGAL PHARMACEUTICALS INC - http://www.madrigalpharma.com.
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MDGL - Q0.1137.18·216.890.5212.04-10.22-4.6625.1132,3989,886221.85  224.68  206.03322.67  119.760419:38:19Apr 1615 min RT 2¢

Recent Trades - Last 10 of 9886
Time ETExPriceChangeVolume
19:38:19Q211.04-11.221
18:37:23Q216.89-5.372
16:32:40Q214.80-7.4650
16:32:40Q214.86-7.4050
16:29:18Q213.00-9.2620
16:22:11Q215.00-7.265
16:22:11Q215.00-7.265
16:19:54Q213.00-9.2625
16:14:08Q213.01-9.253
16:14:08Q213.00-9.2697

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-16 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-04-09 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra(TM) (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
2024-04-03 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 23:59U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
2024-03-18 16:04U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Proposed Public Offering
2024-03-14 16:15U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces FDA Approval of Rezdiffra(TM) (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
2024-03-06 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-03-05 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
2024-02-28 07:01U:MDGLNews ReleaseMadrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
2024-02-28 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-02-08 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
2024-02-06 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-01-29 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Additions to Its Leadership Team
2024-01-22 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-01-04 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
2024-01-03 16:30U:MDGLNews ReleaseMadrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-22 16:30U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-11-27 16:30U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2023-11-21 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer